| abstract |
The present disclosure provides an antibody, or a binding fragment thereof, is provided. The antibody, or a binding fragment thereof, binds specifically to a mucin 13 (MUC13) protein expressed on the surface of a cancer cell. In another embodiment, a pharmaceutical composition is provided. The pharmaceutical composition comprises the antibody, or binding fragment thereof, and a pharmaceutically acceptable carrier, excipient, or diluent. In another embodiment, a method of treating a cancer in a patient is provided. In yet another embodiment, a method of diagnosing a cancer in a patient is provided. In another embodiment, a diagnostic kit is provided, wherein the kit comprises the antibody. In various aspects, the antibody binds to a domain of the MUC13 protein. |